Roche's strong COVID-19 test sales help offset losses in routine screens

By staff writers

July 23, 2020 -- Strong performance in Roche's molecular diagnostics business -- COVID-19 tests in particular -- for the first half of the year helped offset losses for products used in routine practice and restricted during pandemic lockdowns, according to the company's latest earnings report.

For the first half at constant exchange rates, sales in the diagnostics division were up by 3% to CHF 6.1 billion ($6.5 billion U.S.), with molecular diagnostics up by 61%, the company reported. Sales were up in most parts of the world, aside from the Asia Pacific region, which saw a 9% decrease that Roche said was strongly related to the pandemic shutdown in China.
Half-year sales, diagnostics division, 2019-2020*
Division HY 2020, CHF HY 2019, CHF Change, in CHF Change at constant exchange rates
Centralized and point-of-care solutions $3.19B $3.77B -15% -10%
Molecular diagnostics $1.56B $1.03B +51% +61%
Diabetes care $832M $958M -13% -6%
Tissue diagnostics $508M $526M -3% +2%
Total diagnostics $6.01B $6.28B -3% +3%
*Figures are rounded

While there was growth at constant exchange rates for most regions, demand was down in all regions in the second quarter as the pandemic continued to take its toll and routine testing declined along with regular health checks, according to the company.

Uptake of new tests and pharmaceuticals has been strong, Roche said in a statement. New diagnostics launches related to the pandemic included the Elecsys SARS-CoV-2 test, the Roche v-Tac digital platform, and the Elecsys interleukin-6 (IL-6) test.

Overall, first-half sales for the company were up by 1% at constant exchange rates to CHF 29.3 billion ($31 billion) and down by 4% in Swiss francs. Core operating profit was up by 2% at constant exchange rates to CHF $11.7 billion ($12.6 billion) and down by 5% in Swiss francs.

Roche expects low- to mid-single digit sales growth for the rest of the year.

Half-year sales, 2019-2020*
Division 2020, CHF 2019, CHF Change, in CHF Change at constant exchange rates
Pharmaceuticals $23.2B $24.2B -4% 1%
Diagnostics $6.1B $6.3B -3% 3%
Total group $29.3B $30.5B -4% 1%
*Figures are rounded
Thermo Fisher posts 10% growth in Q2
Thermo Fisher Scientific reported financial results for the second quarter, noting 10% revenue growth.
Roche partners with cancer network for personalized care
Roche has partnered with Summit Cancer Centers to help personalize cancer care for patients at Summit's integrated cancer treatment centers in eastern...
COVID-19 powers $5B in molecular diagnostics market growth
The worldwide demand for COVID-19 tests has materialized rapidly from nothing and is on course to become a multibillion-dollar market in 2020, writes...
Quest overall testing volume, revenue decline
Quest Diagnostics reported an 18% decline in overall test volume as part of a look at its preliminary financial results from the second quarter and reported...
Companion diagnostics survive COVID-19 with small nick
The COVID-19 crisis has had a slightly negative, but not critical, impact on the market for companion diagnostics, according to a new market report from...

Copyright © 2020

Last Updated eh 7/23/2020 1:57:50 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current